Oramed Pharmaceuticals (Oramed Pharmaceuticals) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Oramed Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Oramed Pharmaceuticals's Free Cash Flow for the three months ended in Dec. 2023 was $-1.42 Mil. Oramed Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Oramed Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Oramed Pharmaceuticals's current FCF Yield % is -11.34%.

The historical rank and industry rank for Oramed Pharmaceuticals's FCF Margin % or its related term are showing as below:

ORMP' s FCF Margin % Range Over the Past 10 Years
Min: -1051.2 Med: -538.99 Max: 724.8
Current: -787.24

During the past 13 years, the highest FCF Margin % of Oramed Pharmaceuticals was 724.80%. The lowest was -1051.20%. And the median was -538.99%.

ORMP's FCF Margin % is ranked worse than
72.56% of 1035 companies
in the Biotechnology industry
Industry Median: -149.8 vs ORMP: -787.24

Oramed Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Oramed Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals FCF Margin % Chart

Oramed Pharmaceuticals Annual Data

Trend

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-479.28

-462.07

-797.48

-1,051.20

-787.24

Oramed Pharmaceuticals Quarterly Data
	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-1,229.07	-863.06	-393.77	-	-

Competitive Comparison of Oramed Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Oramed Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oramed Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's FCF Margin % falls into.

Oramed Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Oramed Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-10.549	/	1.34
	=	-787.24 %

Oramed Pharmaceuticals's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-1.421	/	0
	=	%

Oramed Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Oramed Pharmaceuticals (Oramed Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (NAS:ORMP) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

OJU1:Germany

Address

1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036

Website

https://www.oramed.com

Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas.

Executives

Benjamin Shapiro	director	1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Nadav Kidron	director, 10 percent owner	142 W. 57TH ST., NEW YORK NY 10019
Yadin Rozov	director	9 TERRACE CIRCLE, ARMONK NY 10504
Miriam Kidron	director	2 ELZA STREET, JERUSALEM L3 93706
Michael Rabinowitz	officer: Chief Commercial Officer	1185 AVENUE OF THE AMERICAS, THIRD FLOOR, NEW YORK NY 10036
Arie Mayer	director	MORAN 16, KFAR SABA L3 4428890
Netanel Derovan	officer: Chief Legal Officer	1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
David Silberman	officer: Chief Financial Officer	20 MAMILLA AVENUE, JERUSALEM L3 9414904
Kevin Rakin	director	36 CHURCH LANE, WESTPORT CT 06880
Michael Rabinowitz	officer: Chief Commercial Officer	MAXIM GROUP, LLC, 405 LEXINGTON AVENUE, NEW YORK NY 10174
Leonard Sank	director	3 BLAIR ROAD, CAPE TOWN T3 8005
Gao Xiaoming	director	11F. NO. 266 HANKOU ROAD, HUANGPU DISTRICT, SHANGHAI F4 2000001
Avraham Gabay	officer: CFO, Treasurer and Secretary	2/4 HIGH-TECH PARK, P.O. BOX 39098, JERUSALEM L3 91390
Mark Daniel Hasleton	officer: VP Business Development	13, HIBAT ZION, RAANANA, RAANANA L3 4338111
Aviad Friedman	director	HADASSA 6, TEL AVIV L3 6451306